Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.22.62 (
caspase-9
)
7,507
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
BACKGROUND Long non-coding RNA (lncRNA)
UCA1
is an oncogene in breast cancer. The purpose of this study was to investigate the role of
UCA1
in tamoxifen resistance of estrogen receptor positive breast cancer cells. MATERIAL AND METHODS Tamoxifen sensitive MCF-7 cells were transfected for
UCA1
overexpression, while tamoxifen resistant LCC2 and LCC9 cells were transfected with UCA siRNA for
UCA1
knockdown. qRT-PCR was performed to analyze
UCA1
expression. CCK-8 assay, immunofluorescence staining of cleaved
caspase-9
, and flow cytometric analysis of Annexin V/PI staining were used to assess tamoxifen sensitivity. Western blot analysis was performed to detect p-AKT and p-mTOR expression. RESULTS LncRNA
UCA1
was significantly upregulated in tamoxifen resistant breast cancer cells compared to tamoxifen sensitive cells. LCC2 and LCC9 cells transfected with
UCA1
siRNA had significantly higher ratio of apoptosis after tamoxifen treatment.
UCA1
siRNA significantly decreased the protein levels of p-AKT and p-mTOR in LCC2 and LCC9 cells. Enforced
UCA1
expression substantially reduced tamoxifen induced apoptosis in MCF-7 cells, while rapamycin treatment abrogated the protective effect of
UCA1
. CONCLUSIONS
UCA1
upregulation was associated with tamoxifen resistance in breast cancer. Mechanistically,
UCA1
confers tamoxifen resistance to breast cancer cells partly via activating the mTOR signaling pathway.
...
PMID:Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway. 2776 38